Research Opportunities

Clinical studies and trials are the force behind the treatment, cure and prevention of any disease. Through the volunteerism of patients and those affected by an illness, knowledge is advanced, and a promise for a cure becomes more of a reality.

Hablamos Español

Memory Screening and Longitudinal Studies of Aging

Longitudinal Study of Normal Aging, Mild Cognitive Impairment (MCI) and Alzheimer’s Disease
Participants receive a comprehensive diagnostic evaluation and are re-evaluated every year. The goal is to improve early diagnosis and better understand the clinical course and causes of age-related cognitive decline and AD.
For information, contact Thet Oo at 212-263-8088; thet.oo@nyumc.org 

Orexin (Hypocretin) and Tau Pathology in Cognitively Normal Elderly: A New Prevention Strategy for Alzheimer’s Diesease (TONE Study)
Our preliminary results suggest that tau pathological changes in the brainstem (years before the onset of clinical symptoms) disrupt the orexinergic system causing sleep disruption, changes in core body temperature (CBT) and further Alzheimer’s disease (AD) type neurodegeneration in a feed forward cycle. We will test this hypothesis in up to 19 cognitively normal older by performing a full clinical evaluation, a tau PET-MR scan, 2 nights of nocturnal polysomnography (PSG), during which we will measure CBT, and a lumbar puncture (LP) to obtain cerebrospinal fluid (CSF). We are currently enrolling male and female participants with normal cognition and 55-75 years of age, whose total sleep time (TST) is between 6-8 hours and absence of moderate to severe Obstructive Sleep Apnea (OSA). For information, contact Margo Miller at 212-263-7563; Margo.Miller@nyumc.org

Sleep, Aging and Risk for Alzheimer’s disease (SARA 2.0 Study)
We are currently undertaking a 24-30 month longitudinal study of 124 subjects in order to analyze the relationship between two common sleep disorders and AD risk. Age-related sleep changes and common sleep disorders like obstructive sleep apnea (OSA) may increase amyloid burden and represent risk factors for cognitive decline in the elderly. Participants must be able to come to the first visit which will include a physical exam, cognitive testing, sleep interview, EKG, clinical labs, and blood sample. We will directly interrogate the brain using a 2-night nocturnal polysomnography (NPSG) and amyloid deposition using C-PiB PET/MR both at baseline and at the 24-month follow-up. We are currently enrolling adults located in the New York City area between the ages of 60 to 75 years old with normal cognition, both male and female, in good general health with approximately 50% having mild to moderate OSA. Participants receive results and are compensated for their time. For information, contact Margo Miller at 212-263-7563; Margo.Miller@nyumc.org

Blood pressure, cerebral perfusion and cognitive performance in hypertension
Hypertension (chronically high blood pressure) may lead to impaired blood delivery to the brain, which can cause brain shrinkage and cognitive decline. The NYU Center for Brain Health invites adults age 65-80, with or without hypertension, to participate in a research study. The purpose of this study is to examine the effects of one’s current blood pressure on their brain, memory and thinking in the future. Your evaluation will include clinical exams, memory testing, bloodwork, ECG, carotid ultrasound, an MRI of the brain, and 24–hour ambulatory blood pressure monitoring. For information, contact Catherine Randall at 212-263-7563; catherine.randall@nyumc.org

Imaging Brain Inflammation using Positron Emission Tomography (PET)
We hope to learn whether high blood pressure is associated with increased levels of brain inflammation using the technique of Positron Emission Tomography (PET).  PET scanning measures brain activity by imaging small amounts of radioactivity emitted during scanning.  The type of PET scan used in this study is designed to help researchers learn about inflammation in the brain.  Inflammation is an important process that helps the body protect itself from infection and foreign substances, though inflammation can sometimes cause problems when it is excessive or inappropriate.  In addition to the PET scan, study assessments may include MRI and memory testing.  We are currently enrolling subjects with high blood pressure.  Participants are compensated for their time and effort. For information, contact Patrick Harvey at 212-263-7563; patrick.harvey@nyumc.org

Cognitive Detection of Preclinical Alzheimer’s: Validation Using Biomarkers
Detection of Alzheimer’s disease during its early (or preclinical) stage has become very important for developing treatments to slow down or prevent the disease. Biomarkers, such as a positron emission tomography – computed tomography (PET-CT) scan for detecting amyloid in the brain, have been developed to detect Alzheimer-related brain pathology, but these methods are invasive, expensive or both. This study will confirm new computer memory and thinking tests (known as cognitive tasks) that may detect memory problems in the preclinical stage of Alzheimer’s when there are no symptoms. Participants will perform the cognitive tasks and receive a PET-CT scan. Performance on the tasks will be compared to the scan results to discover if the tests can identify people who may have brain amyloid. You may join this study if you are between the ages of 60 to 85, inclusive and are in general good health. For information, contact Anaztasia Ulysse 212-263-5845; ADClinicaltrials@nyumc.org

Neurotrack Test Validation
Detection of Alzheimer’s disease during its early (preclinical) stage has become very important for developing treatments to slow down or prevent the disease. Biomarkers, such as the Magnetic Resonance Imaging (MRI) scan for detecting the shrinkage of brain regions, have been developed to detect Alzheimer-related brain pathology, but these methods are invasive, expensive or both. This study will validate new computer memory and thinking tests (known as cognitive tasks) that may detect memory problems in the preclinical stage of Alzheimer’s when there are no symptoms. Participants will perform the cognitive tasks and receive an MRI scan. Performance on the cognitive tasks will be compared to the scan results to discover if the tests can evaluate people at risk for developing Alzheimer’s. You may join this study if you are between the ages of 60 to 85, inclusive and are in general good health. For information, contact Anaztasia Ulysse 212-263-5845; ADClinicaltrials@nyumc.org


To be eligible for a clinical trial, prospective participants should be on a stable medication dosage, present no other brain diseases (for example, Parkinson's or stroke), be cancer free for a minimum of two years, cardiovascular disease free for a minimum of six months, and have a study partner who can accompany them to clinic visits. For information on Clinical Trials or to schedule a screening visit, please contact: Jamika Singleton-Garvin, Anaztasia Ulysse or Shannon Chen; Clinical Trials numbers: 212-263-5708/ 0771 / 5845; Email: ADClinicaltrials@nyumc.org

Studies for those with Mild Cognitive Impairment and/or Alzheimer’s Disease

SUVN-502 as Treatment for Subject with Moderate Alzheimer’s Disease currently treated with Donepezil Hydrochoride and Memantine Hydrochloride
This is a phase 2 research trial of an oral investigational medication called SUVN-502 that is meant to test the effect on the symptoms of moderate Alzheimer’s disease when given alongside standard treatments of donepezil and Mementine (both supplied by the study). The trial is for individuals who are between the ages of 50 and 85 that have been diagnosed with Alzheimer’s disease for at least a year. Participation consists of 26 weeks of “double blind” (possibility of placebo) treatment and a mandatory caregiver. Please note that participants cannot be taking any other Alzheimer’s disease medication except for Donepezil (Aricept) and Mementine (Namenda) during the course of the trial. For information, contact Anaztasia Ulysse 212-263-5845; ADClinicaltrials@nyumc.org

Aducanumab (BIIB037) as Treatment for Early Alzheimer’s Disease (MCI) (Biogen Study)
We are offering a study to determine whether the anti-amyloid monoclonal antibody Aducanumab, administered as an intravenous infusion once every four weeks would slow down the cognitive decline in individuals with Prodromal AD. To be eligible, individuals must be between the ages of 50 to 85 and have a positive amyloid PET Scan, which will be done as part of the study.  For information, contact Anaztasia Ulysse 212-263-5845; ADClinicaltrials@nyumc.org

Therapeutic Effects of Exercise in Adults with Amnestic Mild Cognitive Impairment (EXERT Study)
EXERT is a national, 18-month long, clinical trial to test whether physical exercise can slow the progression of early Alzheimer’s disease related memory problems or mild cognitive impairment in older adults. Participants must be able to exercise at a participating local YMCA 4 times per week for 18 months (duration of the study). Participants must also be able to come to the clinic for physical exams, blood collection, cognitive testing, and brain imaging. Eligible adults must be willing to participate in either of the two exercise treatment assignment groups. We are currently enrolling adults between the ages of 65 and 89 years who are experiencing mild memory loss or lapses and/or are diagnosed with Mild Cognitive Impairment, have not been regularly exercising, and are in good health otherwise. For information, contact Anaztasia Ulysse 212-263-5845; ADClinicaltrials@nyumc.org

LY3314814 (BACE Inhibitor) as treatment for subjects with Mild Alzheimer’s Disease Dementia (The Daybreak Study)
Currently EnrollingFor information, contact Anaztasia Ulysse 212-263-5845; ADClinicaltrials@nyumc.org

Long-Term Nicotine Treatment of Mild Cognitive Impairment (MIND)
The Memory Improvement Through Nicotine Dosing (MIND) study will deteremine whether daily transdermal nicotine will have a positive effect on early memory loss in people diagnosed with MCI. We need your help. If you are a healthy, non-smoking adult age 55+ and are interested in learning more about this study. There is no cost to participate. For information, contact Shannon Chen 212-263-5845; ADClinicaltrials@nyumc.org

Alzheimer’s Disease Neuroimaging Initiative 3 (ADNI3) Protocol
Currently Enrolling. For information, contact Shannon Chen 212-263-5848; ADClinicaltrials@nyumc.org

Studies for the Prevention of Cognitive Impairment

A Proof of Concept Study of the Prevention of Mild Cognitive Impairment and Eventual Alzheimer’s Disease Using F18 Flutemetamol. For information, contact Anaztasia Ulysse 212-263-5845; anaztasia.ulysse@nyumc.org

Solanezumab to Prevent or Delay Onset of Alzheimer’s Disease (the A4 Study)
After promising findings in a recent study involving the anti-amyloid monoclonal antibody solanezumab, we will be running another intravenous infusion trial with solanezumab in cognitively normal adults who are believed to be at higher risk for developing Alzheimer’s disease. This monoclonal antibody aims to reduce harmful amyloid build-up in the brain. Researchers hope that this drug will prevent or delay the onset of Alzheimer's disease. Infusions are every 4 weeks for about 3 years. For information, contact Anaztasia Ulysse 212-263-5845; ADClinicaltrials@nyumc.org

Intramuscular Injection (CAD106) and BACE (β-secretase) Inhibitor (CNP520) to prevent or delay onset of Alzheimer’s Disease in people that are Positive for the APOE4 Gene (The Generation Study)
Currently Enrolling For information, contact Anaztasia Ulysse 212-263-5845; ADClinicaltrials@nyumc.org

A randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of CNP520 in participants at risk for the onset of clinical symptoms of Alzheimer’s Disease (Generation 2)
Enrollment in December 2018